陽光城(000671.SZ):上海嘉聞已於9月9日通過大宗交易減持4100.3391萬股
格隆匯 9 月 9日丨陽光城(000671.SZ)公佈,信息披露義務人於2020年9月9日通過大宗交易減持上市公司4100.3391萬股股份,占上市公司總股本的1.00%;同日,上海嘉聞與泰康人壽、泰康養老籤訂《股份轉讓協議》,上海嘉聞擬通過協議轉讓方式轉讓上市公司13.53%股份(計554,710,264股),其中泰康人壽受讓8.53%股份(計349,693,308股)、泰康養老受讓5.00%股份(計205,016,956股)。
此次權益變動後,上海嘉聞持有公司股份104,453,225股,持股比例由17.08%降至2.55%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.